PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects Prostate Cancer," (1) demonstrating clinical validation ...
Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...
The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023. The ...
TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...
Final random-forest-based models outperformed all publicly available risk scores on internal and external test sets.
The next breakthrough in cancer screening is emerging from the convergence of artificial intelligence and canine biology. That’s the thesis behind SpotitEarly, a startup that recently launched in the ...
Head and neck cancers represent a biologically heterogeneous group of malignancies requiring accurate diagnosis, staging, and risk stratification for ...
Spread the loveIn a groundbreaking study, researchers from Sweden have unveiled an artificial intelligence (AI) system capable of predicting the risk of melanoma years before it manifests. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results